Hence, CML disease status may reflect a diverse intracellular network responsible for different responses to BCL2 inhibition alone or combined with BCR-ABL1 kinase inhibitor. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.